Search
for
Sort by
Research 30 of 1000+
- Identification of drug-specific public TCR driving severe cutaneous adverse reactions
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series
- Cutaneous adverse drug reaction associated with topical use of benzyl benzoate in a dog
- Cutaneous Adverse Drug Reactions to Antibiotics: How Much is the Extent of the Problem?
- A clinical study of cutaneous adverse drug reactions
- Adverse cutaneous reactions to soft tissue fillers – a review of the histological features
- Adverse Cutaneous Reactions to Mood Stabilizers
- Adverse Cutaneous Reactions to Antidepressants
- Adverse Cutaneous Reactions to Antipsychotics
- Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Severe cutaneous adverse reactions to drugs
- A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
- Faculty Opinions recommendation of Identification of drug-specific public TCR driving severe cutaneous adverse reactions.
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Adverse Reactions Following Intradermal Injection of Exosome‐Based Formulations: A Case Series
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Cutaneous Reactions to Drugs
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors